AstraZeneca PLC · LSE:AZN
AstraZeneca — Investor Day (2000)
16 slides from AstraZeneca's investor day presentation, 2000
Slide 1: AstraZeneca GI Franchise
A AstraZeneca GI Franchise Dr Martin Nicklasson Executive Vice President, GI Franchise GI Franchise highlights b Nexium® approval in Europe b Nexium® launch in several countries b Grants of Nexium® related patents b Successful defence of intellectual property for Losec® A Martin Nicklasson - GI Page
Slide 2: AstraZeneca objectives in GI
AstraZeneca objectives in GI b Continue sales growth of Losec®/Prilosec® b Defence of Losec®/Prilosec® patents b Successfully launch Nexium® b Extend the opportunities within the GI pipeline A Losec®/Prilosec® highlights in 2000 b Losec® MUPS® approved in 8 and launched in 14 countries b Expansion o
Slide 3: Pediatric filing status in the US
Pediatric filing status in the US b Filing for pediatric use on schedule b As specified by FDA Modernisation Act, AstraZeneca anticipates receiving an additional 6 months of market exclusivity for Prilosec® A GI Franchise – intellectual property and litigation Substance Country patent expiry Status
Slide 4: Remaining sales after patent expiry
GI Franchise – intellectual property and litigation Substance Country patent expiry Status Australia April 1999 1 generic Germany * April 1999 14 generics Malaysia April 1999 2 generics Singapore April 1999 3 generics Hong Kong April 1999 13 generics * SPC nullified and under appeal A Sales erosion
Slide 5: Status of US litigation processes (omeprazole ANDAs)
Status of US litigation processes (omeprazole ANDAs) Company Appl. Date of Lawsuits Expiry of Number notice (filing date by 30-month AstraZeneca) stay period Genpharm 75-268 Apr 1998 May 1998 Oct 2000 Genpharm 75-268 Oct 1998 Nov 1998 Apr 2001 Andrx 75-347 Apr 1998 May 1998 Oct 2000 Andrx 75-347 Jun
Slide 6: In summary – Losec/Prilosec
In summary – Losec®/Prilosec® b The MUPS® tablet launched in 14 countries in 2000 b Filing for pediatric use on schedule in US b Sales - post-substance patent expiry - significantly better maintained compared to other models b Compared to 1999, no additional countries facing generic competition b Th
Slide 7: Nexium launches in 2000 and 2001
Nexium® – launches in 2000 Germany Sweden Denmark Aug Sept Oct Nov Dec UK Ireland Norway A Nexium® – launches in 2001 USA Singapore Canada Austria Argentina Hong Kong S. Africa Finland S. Korea Thailand Philippines Holland Iceland Brazil Mexico Q1 Q2 Q3 Q4 Australia Belgium Luxembourg Portugal Spain
Slide 8: US launch of Nexium
US launch of Nexium® Strategic Platform b Drive demand through megabrand levels of promotion: – Professional initiatives – Consumer initiatives b Provides value to managed care and consumers A Initial reactions to Nexium® in its first markets b High awareness in the market place b Highly positive re
Slide 9: UK and German launch of Nexium
UK launch of Nexium® Cumulative Rxs 30000 25000 20000 15000 10000 5000 0 Avandia® Lipitor® Vioxx® Seretide® Viagra® Nexium® Source: Scriptcount (10 week data) A German launch of Nexium® Weekly Rxs 25000 Nexium® MUPS® Vioxx® 20000 Celebrex® Seretide® 15000 10000 5000 0 1st week 2nd week 3rd week 4th
Slide 10: Swedish launch of Nexium
Swedish launch of Nexium® Index 400 Nexium® Lipitor® 300 Losec® Lanzo® Pantoloc® 200 Pariet® 100 0 1 2 3 4 5 6 7 8 9 10 11 12 Source: Svensk Läkemedelsstatistik Months since launch A Martin Nicklasson - GI Page 10
Slide 11: Acid control
Acid control Day 5 100 Nexium® % patients / subjects 80 40 mg omeprazole 60 40 mg lansoprazole 30 mg 40 pantoprazole 40 mg 20 0 pH above 4 for at least 12 hours Röhss et al Nordic Gastro 2000, Thomson et al DDW 2000, Wilder-Smith et al DDW 2000 P < 0.05 percentage of time with intragastric pH above
Slide 12: Acid control
Acid control Day 1 100 Nexium® 80 40 mg lansoprazole % subjects 60 30 mg 40 20 0 12 hours 16 hours pH above 4 for at least: Thomson et al UEGW 2000 P < 0.005 percentage of time with intragastric pH above 4 during 24 hours A Acid control Day 5 100 Nexium® 80 40 mg % subjects rabeprazole 60 20 mg 40 2
Slide 13: Acid control; Nexium leads to economic benefits
Acid control Day 5 100 Nexium® 80 20 mg lansoprazole % subjects 60 15 mg 40 20 0 12 hours 16 hours pH above 4 for at least: Wilder-Smith et al UEGW 2000 P < 0.026 percentage of time with intragastric pH above 4 during 24 hours A Nexium® leads to economic benefits Improved clinical Patient management
Slide 14: Clinical superiority of Nexium reduces costs
Clinical superiority of Nexium® in healing erosive esophagitis leads to reduction in costs UK medical practice Direct medical costs per treatment (£) 0 20 40 60 80 Nexium® 40 mg 14% reduction in direct medical costs Drug Consultations & endoscopies Losec® 20 mg Wahlqvist P 2000, ISPOR (abstract) Kah
Slide 15: Ongoing key studies and sNDAs
Ongoing key studies b More than 30,000 patients in clinical trials globally b Comparative studies against other PPIs b Treatment of GERD patients with 5 year follow-up b Health economics in GERD A Ongoing sNDAs b Dyspepsia b Treatment of NSAID GI side-effects b Treatment of children with GERD b Pare
Slide 16: In summary – Nexium; In conclusion
In summary – Nexium® b Successfully launched in 6 European markets with high awareness and positive reactions from doctors b New data confirm improved acid control versus all other PPIs b Provides value for money compared to standard treatment with Losec® b Comparative studies with other PPIs ongoin